PYPD Polypid

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025.

Company Webcast

The webcast presentation will take place at 10:15 a.m. ET on Thursday, May 29, 2025. The webcast can be accessed by visiting the conference home page at or directly at . The webcast will also be available for replay following the event.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at or register for the event at .

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit and follow us on and .

Contacts:

PolyPid Ltd. 

Ori Warshavsky

COO – US

908-858-5995

Investors:

Brian Ritchie

LifeSci Advisors

212-915-2578



EN
20/05/2025

Underlying

PYPDPolypid

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Polypid

 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Con...

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025. Company Webcast The webcast presentation will take place at 10:15 a.m. ET on Thursday, May 29, 2025. The webcast can be a...

17h / 15m 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Provides Corporate Update and Reports First Quarter 2025 Finan...

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100, with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 14, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company ai...

May 14, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Report First Quarter 2025 Financial Results and Operational...

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 14, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business ope...

April 29, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Participate in The Citizens Life Sciences Conference

PolyPid to Participate in The Citizens Life Sciences Conference PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in a fireside chat at The Citizens Life Sciences Conference taking place in New York, NY, from May 7-8, 2025. Citizens Life Sciences Conference Fireside ChatDate:Wednesday, May 7, 2025Time:10:30 AM ET   The PolyPid management team will participate in one-on-one investor meetings duri...

April 22, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIEL...

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections Last Patient Enrolled Following Positive Recommendation by DSMB to Conclude Enrollment of Phase 3 Trial at 800 Patients; Top-line Results Expected by End of Q2 2025 and, if Positive, Expected to be Followed by Submission of an NDA to the FDA Leveraging the Company’s Fast-Track and Breakthrough Therapy Designations PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“PolyPid” or the “Company”), a late-stage bio...

March 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch